Compare GE Vernova Inc (GEV) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Humana Inc — how do they compare? GE Vernova Inc trades at $1,038.74 (market cap $269.50B), while Humana Inc trades at $374.25 (market cap $44.77B). The key difference: GE Vernova Inc is far larger — about 6× Humana Inc's market cap, and Humana Inc pays the higher dividend (0.95%). Which is the better fit depends on your goals.
| GEV | HUM | |
|---|---|---|
Market Cap | $269.50B | $44.77B |
Sector | Technology | Health |
52-Week High | $1.17K | $409.42 |
52-Week Low | $547.96 | $163.67 |
Enterprise Value | $259.17B | $52.12B |
Dividend Yield | 0.2% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,042.98, up 5.26% over 24 hours, reflecting strong momentum near its pivot point of $1,017. The stock exhibits bullish technical signals with moving averages supporting the uptrend. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $17.44 significantly exceeding expectations, though Q2 2026 saw a miss. Revenue growth is solid, projected to rise from $38.07B in 2025 to $41.4B in 2026, while net income margin expanded to 23.04%. The company benefits from a massive $176 billion backlog, positioning it to capitalize on AI-driven power demand.
Outlook remains positive given GEV's strategic role in addressing AI infrastructure bottlenecks, but high valuations (P/E 29.01, EV/EBITDA 86.33) pose risks if execution falters. Analyst consensus is strongly bullish with a $1,270 price target, though investors should monitor quarterly execution against lofty expectations and competitive pressures in the energy sector.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
